Thomas P. Frye, DO, presented “Point Counterpoint: MRI” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.

This content is available free to the GRU Community. Login or create an account to view it.


Create an Account

How to cite: Frye, Thomas P. Point Counterpoint: MRI.” November, 2023. Accessed Jun 2024.

Point Counterpoint: MRI – Summary

Thomas P. Frye, DO, argues in favor of multiparametric magnetic resonance imaging (mpMRI) over micro ultrasound (microUS) for prostate imaging. He begins by stating the underlying goals of prostate imaging in the context of triaging in urologic oncology.

Dr. Frye then turns to the lack of data in support of microUS over mpMRI. He highlights that prostate imaging from microUS lacks the scale and reliable interpretability of mpMRI.

Dr. Frye supports the effectiveness of mpMRI in detecting clinically significant prostate cancer with data from the PROMIS and PRECISION studies. He notes that the use of mpMRI in screening can prevent unnecessary biopsies of insignificant cancers.

He concludes by reviewing weaknesses in recent studies of microUS. He presents a clinical analysis of microUS which demonstrated the superiority of conventional imaging (TRUS) and mpMRI over microUS.

Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.